## Nadera Sweiss

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8241505/publications.pdf

Version: 2024-02-01

117571 143943 3,407 57 34 57 h-index citations g-index papers 57 57 57 4010 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 32-38.	0.5	394
2	Ocrelizumab, a humanized anti D20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placeboâ€controlled, doseâ€ranging study. Arthritis and Rheumatism, 2008, 58, 2652-2661.	6.7	193
3	Racial Difference in Sarcoidosis Mortality in the United States. Chest, 2015, 147, 438-449.	0.4	174
4	Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction. Circulation: Cardiovascular Imaging, 2016, 9, e003738.	1.3	167
5	Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis. Current Opinion in Pulmonary Medicine, 2013, 19, 545-561.	1.2	145
6	Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis. Journal of Cardiovascular Electrophysiology, 2012, 23, 925-929.	0.8	135
7	Rituximab in the treatment of refractory pulmonary sarcoidosis. European Respiratory Journal, 2014, 43, 1525-1528.	3.1	133
8	Established and experimental medical therapy of pulmonary sarcoidosis. European Respiratory Journal, 2013, 41, 1424-1438.	3.1	109
9	Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations. PLoS ONE, 2010, 5, e9088.	1.1	105
10	Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. European Journal of Heart Failure, 2011, 13, 1231-1237.	2.9	97
11	Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. European Respiratory Review, 2020, 29, 190146.	3.0	92
12	Rheumatologic Manifestations of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 463-473.	0.8	80
13	Identification of a Novel Tollâ€ike Receptor 7 Endogenous Ligand in Rheumatoid Arthritis Synovial Fluid That Can Provoke Arthritic Joint Inflammation. Arthritis and Rheumatology, 2016, 68, 1099-1110.	2.9	78
14	Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung, 2017, 195, 313-322.	1.4	75
15	CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. Cellular and Molecular Life Sciences, 2020, 77, 1387-1399.	2.4	74
16	Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Design, Development and Therapy, 2014, 8, 349.	2.0	70
17	The Novel Role of IL-7 Ligation to IL-7 Receptor in Myeloid Cells of Rheumatoid Arthritis and Collagen-Induced Arthritis. Journal of Immunology, 2013, 190, 5256-5266.	0.4	69
18	Management of extrapulmonary sarcoidosis: challenges and solutions. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1623-1634.	0.9	66

#	Article	IF	CITATIONS
19	Suppression of Myocardial 18F-FDG Uptake Through Prolonged High-Fat, High-Protein, and Very-Low-Carbohydrate Diet Before FDG-PET/CT for Evaluation of Patients With Suspected Cardiac Sarcoidosis. Clinical Nuclear Medicine, 2017, 42, 88-94.	0.7	63
20	Ligation of TLR5 Promotes Myeloid Cell Infiltration and Differentiation into Mature Osteoclasts in Rheumatoid Arthritis and Experimental Arthritis. Journal of Immunology, 2014, 193, 3902-3913.	0.4	62
21	Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opinion on Biological Therapy, 2009, 9, 889-895.	1.4	58
22	Cardiac Sarcoidosis Detected by Late Gadolinium Enhancement and Prevalence of Atrial Arrhythmias. American Journal of Cardiology, 2014, 113, 1556-1560.	0.7	55
23	IgA Anti-Î <sup>2</sup> 2-Glycoprotein I Autoantibodies Are Associated with an Increased Risk of Thromboembolic Events in Patients with Systemic Lupus Erythematosus. PLoS ONE, 2010, 5, e12280.	1.1	54
24	Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography, 2016, 33, 1344-1352.	0.3	53
25	Bone Health Issues in Sarcoidosis. Current Rheumatology Reports, 2011, 13, 265-272.	2.1	52
26	Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Multiple Sclerosis Journal, 2008, 14, 809-814.	1.4	50
27	Clinical Characteristics of Patients With Anti-Jo-1 Antibodies. Journal of Clinical Rheumatology, 2009, 15, 254-255.	0.5	45
28	Macrophages are the primary effector cells in IL-7-induced arthritis. Cellular and Molecular Immunology, 2020, 17, 728-740.	4.8	45
29	Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis. Annals of the Rheumatic Diseases, 2015, 74, 1898-1906.	0.5	44
30	Refractory Pulmonary Sarcoidosis. Clinical Pulmonary Medicine, 2016, 23, 67-75.	0.3	43
31	Drug-Induced Granulomatous Interstitial Nephritis in a Patient With Ankylosing Spondylitis During Therapy With Adalimumab. American Journal of Kidney Diseases, 2010, 56, e17-e21.	2.1	42
32	Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clinics in Dermatology, 2007, 25, 341-346.	0.8	36
33	Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arquivos De Gastroenterologia, 2011, 48, 91-97.	0.3	36
34	Angiogenesis in Rheumatoid Arthritis Is Fostered Directly by Tollâ€like Receptor 5 Ligation and Indirectly Through Interleukinâ€17 Induction. Arthritis and Rheumatism, 2013, 65, 2024-2036.	6.7	36
35	Utility of Lip Biopsy in the Diagnosis and Treatment of Sjogren's Syndrome. Laryngoscope, 2007, 117, 1004-1008.	1.1	35
36	Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status. Annals of the Rheumatic Diseases, 2017, 76, 731-739.	0.5	35

#	Article	IF	Citations
37	Nonsteroidal therapy of sarcoidosis. Current Opinion in Pulmonary Medicine, 2013, 19, 516-523.	1.2	34
38	IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion. Cellular and Molecular Immunology, 2021, 18, 2199-2210.	4.8	31
39	Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis. Current Rheumatology Reports, 2010, 12, 8-18.	2.1	29
40	Circulating cytokines in sarcoidosis: Phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine, 2013, 61, 906-911.	1.4	28
41	The minor salivary gland biopsy as a diagnostic tool for Sjogren syndrome. Laryngoscope, 2009, 119, 1922-1926.	1.1	26
42	Linkage of Type I Interferon Activity and TNF-Alpha Levels in Serum with Sarcoidosis Manifestations and Ancestry. PLoS ONE, 2011, 6, e29126.	1.1	25
43	TLR7 endogenous ligands remodel glycolytic macrophages and trigger skinâ€ŧoâ€joint crosstalk in psoriatic arthritis. European Journal of Immunology, 2021, 51, 714-720.	1.6	18
44	Hypoalbuminemia is related to inflammation rather than malnutrition in sarcoidosis. European Journal of Internal Medicine, 2018, 53, e14-e16.	1.0	17
45	FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab. Clinical Nuclear Medicine, 2016, 41, 417-418.	0.7	14
46	Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. European Respiratory Review, 2020, 29, 190147.	3.0	11
47	Clinical and radiological features of Takayasu's arteritis patients in Jordan. Rheumatology International, 2010, 30, 1449-1453.	1.5	10
48	Expression Profiling Elucidates a Molecular Gene Signature for Pulmonary Hypertension in Sarcoidosis. Pulmonary Circulation, 2016, 6, 465-471.	0.8	10
49	Lenalidomide for the Treatment of Cryoglobulinemia and Undifferentiated Spondyloarthropathy in a Patient With Multiple Myeloma. Journal of Clinical Rheumatology, 2010, 16, 90-91.	0.5	9
50	FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: A rationale for using FGD PET-CT for cardiac sarcoid evaluation. Journal of Nuclear Cardiology, 2019, 26, 486-492.	1.4	9
51	Biologic Agents for Rheumatoid Arthritis. Journal of Infusion Nursing, 2009, 32, S4-S17.	1.2	7
52	Sarcoid Pericarditis and Large Vessel Vasculitis Detected on FDG PET/CT. Clinical Nuclear Medicine, 2016, 41, 661-663.	0.7	7
53	Serial FDG-PET/CT Imaging in the Management of Cardiac Sarcoidosis. Clinical Nuclear Medicine, 2018, 43, e50-e52.	0.7	7
54	MRI and FDG PET/CT Imaging Manifestations of Cardiac Sarcoidosis. Clinical Nuclear Medicine, 2015, 40, 973-974.	0.7	6

#	Article	IF	CITATIONS
55	Salivary glands sarcoidosis. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2008, 19, 234-236.	0.1	4
56	Using and Interpreting 18F-FDG PET/CT Images in Patients Referred for Assessment of Cardiac Sarcoidosis: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 2039-2039.	2.8	4
57	Prognostic Impact of FDG-PET/CT ImagesÂin Patients With SuspectedÂCardiacÂSarcoidosis. JACC: Cardiovascular Imaging, 2019, 12, 217-219.	2.3	1